A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (117 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-06-10. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: mdstherapymarrowtransplantradiation
  Phrases that lowered it: participantsparticipantopen labelweekdrug
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports with a death: 49.7% (raises risk) · Drug's FDA history
• Phase: 1 (lowers risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 161 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 838 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor's past termination rate: 8.6% (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Number of arms: 6 (lowers risk) · Design
• Drug's FAERS reports marked serious: 98.6% (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) NCT02892318 · started 2016 · scored riskier than 21% of active trials completed
• A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia NCT03922477 · started 2019 · scored riskier than 41% of active trials terminated
• A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) NCT05709093 · started 2023 · scored riskier than 74% of active trials terminated
• Nivolumab With Chemotherapy in Refractory MDS NCT03259516 · started 2017 · scored riskier than 68% of active trials terminated
• Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab NCT03286114 · started 2017 · scored riskier than 80% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.